Cohance Lifesciences Limited (NSE:COHANCE)
India
· Delayed Price · Currency is INR 1,015.00
-12.00 (-1.17%)
Jun 10, 2025, 3:30 PM IST
Cohance Lifesciences Revenue
In the fiscal year ending March 31, 2025, Cohance Lifesciences had annual revenue of 11.98B INR with 13.91% growth. Cohance Lifesciences had revenue of 4.02B in the quarter ending March 31, 2025, with 58.94% growth.
Revenue
11.98B
Revenue Growth
+13.91%
P/S Ratio
32.42
Revenue / Employee
10.04M
Employees
1,193
Market Cap
388.31B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 271.45B |
| Apollo Hospitals Enterprise | 217.94B |
| Mankind Pharma | 122.07B |
| Zydus Lifesciences | 232.42B |
| Aurobindo Pharma | 317.24B |
| Alkem Laboratories | 129.65B |